Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be ...

The Royal Danish Embassy in Thailand, in collaboration with Novo Nordisk Pharma (Thailand) Ltd. (“Novo Nordisk”), organised ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

A decision is expected in the fourth quarter of 2025.

A Maryland man has filed a lawsuit against the manufacturers of Ozempic, alleging that his use of the drug led to him ...

In a major clinical trial, the weight loss drug Wegovy has been able to treat a serious form of liver disease in the majority ...

US biotech Biohaven last week received a commitment from Oberland Capital to invest up to $600 million in the company. Also, ...

The US Food and Drug Administration (FDA) has accepted Novo Nordisk’s new drug application (NDA) submission for the 25 mg oral formulation of Wegovy (semaglutide) intended for chronic weight ...

PLAINSBORO, N.J., April 29, 2025 /PRNewswire/ -- Today, Novo Nordisk announced it is expanding ... We believe patients living with this chronic disease who want and need treatment under the ...

executive vice president of Product & Portfolio Strategy at Novo Nordisk. "Our investment into the understanding and treatment of obesity continues to reveal new insights, with semaglutide showing its ...

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be presented at ECO 2025 - covering burden, and the value of treatment and ...